Taiwan is, in many ways, a healthcare model for Asia. The island has had universal health coverage for over 30 years and Taiwan’s life expectancy today is almost 81 years, putting it behind only Japan, South Korea, and Singapore in its region. However, by the early 2020s, this rapidly ageing population, along with low birth rates, rising incidence of chronic diseases, continuous underfunding, and staff shortages, were all putting the system under severe strain.
Deeply aware of the issues facing Taiwanese healthcare as a qualified physician, William Lai’s 2024 presidential election campaign proposed a future-proofed system under the slogan, ‘Healthy Taiwan.’ Following up on his campaign pledges, President Lai (one of the few medical doctors currently serving as a head of state, along with counterparts from Albania, Iran, and the Seychelles), launched the Healthy Taiwan Initiative upon his inauguration in May 2024. The initiative aims to transform Taiwan’s healthcare model from one focused on disease treatment to one that instead emphasises prevention, wellness, and health promotion.
In its first phase, the Healthy Taiwan Cultivation Plan, a five-year blueprint from 2025 up to 2029 backed by NTD 48.9 billion (around USD 1.5 billion) in funding, will focus on improving conditions for the healthcare workforce, training more specialists, strengthening the primary care and referral networks, and using AI and big data to improve care.
This last point is one in which Taiwan is particularly well placed to capitalise on, thanks to its long legacy in semiconductor innovation as well as universal health insurance data containing reimbursement records, comprehensive imaging and lab results from all 23 million Taiwanese citizens.
Beyond these flagships, specific programs have also been launched for chronic diseases, cancer screening (cancer has been the leading cause of death on the island for over 40 years), mental health support, and long-term care/healthy ageing (a vital issue on the island, where 4.7 million citizens are over 65, meaning that 18 percent of the population consumes 42 percent of healthcare expenditure).
Responses from private industry – which stands to benefit from the mood of collaboration, innovation, and action permeating Taiwan today – have thus far been glowing, as stakeholders stand to benefit from improved trial frameworks, fast-track market access mechanisms, hospital infrastructure upgrades, and access to a wealth of health data.
The Healthy Taiwan Cultivation Plan “marks a decisive shift from treatment to prevention,” says Wallace Lin of Taiwan Bio, an association of local biotechs. “It expands healthcare beyond hospital settings into home care, telemedicine, digital health, and data-driven disease management, crystallising five decades of strategic continuity.”
New funding is also allowing for much-needed upgrades to the island’s healthcare infrastructure, which caps on expenditure under the National Health Insurance (NHI) budgeting system have historically prevented.
As CW Chen of the International Research-Based Pharmaceutical Manufacturers Association (IRPMA) points out, “Current health expenditure has increased to 7.3 percent of GDP over the past two years; a clear signal of the government’s commitment to long-term sustainability and improved public health outcomes.”
“Our members view this initiative as presenting tremendous opportunities,” adds Carl Wegner from the American Chamber of Commerce. “Taiwan offers a unique proposition,” he continues, “the national healthcare system has operated for decades, creating a data environment that is both comprehensive and reliable. This represents one of the best opportunities globally for pharmaceutical companies, whether for selling products, conducting trials, or leveraging real-world evidence. The historical depth of data, combined with full population coverage, is genuinely unmatched.”
Vincent Tong of MSD – which has around 130 active clinical trials on the island – agrees, noting a willingness on the part of the Taiwanese government to collaborate with pharma sponsors like never before.
“The Healthy Taiwan initiative has created a framework that has aligned government and industry around shared priorities,” says Tong, a Hong Kong native who spent time in Taiwan earlier in his career and recently returned as general manager.
“Crucially, healthcare is now framed as an investment rather than an expense,” adds Tong, who is hopeful of introducing more of the company’s innovative global portfolio of oncology, vaccines, and infectious disease drugs to Taiwan in the coming years.
Key to bringing more new medicines to Taiwan’s population will be the island’s drug regulator, the Taiwan FDA (TFDA), historically the target of industry criticism for its unpredictability, slow decision-making and unclear mechanisms for high-value innovation.
However, the signs are also looking positive there, with TFDA Director General Chih-Kang Chiang proclaiming that, under the auspices of Healthy Taiwan, “Innovation must be matched by implementation.”
He adds, “TFDA plays a central role in this process by maintaining scientific integrity while introducing regulatory flexibility that helps innovative products reach patients faster in Taiwan and move efficiently toward international certification.”
Ongoing TFDA efforts on this front include advancing a regenerative medicines act, offering enhanced guidance and capacity-building services to innovators, using Taiwan’s mass of health data to foster evidence-based regulation, and engaging in greater inter-agency collaboration to bolster research infrastructure and preparedness.
While Taiwan generates more international headlines for its well-publicised geopolitical headaches than its healthcare reforms, the Healthy Taiwan initiative is worthy of far greater coverage. A genuinely transformational plan, the initiative builds on a strong legacy of access, data generation, and quality care, with concrete funding commitments and inter-sectoral buy-in. Already, there has been a noticeable uptick in the use of preventive services and mental health support in Taiwan, with genuine potential that Taiwan can become the Asian leader in health outcomes and innovation in the coming years.
